Cetera Advisor Networks LLC Anavex Life Sciences Corp. Transaction History

Cetera Advisor Networks LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$5.04 - $9.95 $46,428 - $91,659	-9,212 Reduced 13.37%	59,664 $555,000
Q3 2023 Nov 14, 2023	SELL	$6.55 - $9.37 $96,953 - $138,694	-14,802 Reduced 17.69%	68,876 $451,000
Q2 2023 Aug 09, 2023	BUY	$7.66 - $9.5 $37,020 - $45,913	4,833 Added 6.13%	83,678 $680,000
Q1 2023 May 15, 2023	BUY	$8.32 - $11.75 $77,267 - $109,122	9,287 Added 13.35%	78,845 $675,000
Q4 2022 Feb 14, 2023	BUY	$7.65 - $14.43 $50,658 - $95,555	6,622 Added 10.52%	69,558 $644,000
Q3 2022 Nov 10, 2022	BUY	$8.9 - $12.86 $41,429 - $59,863	4,655 Added 7.99%	62,936 $649,000
Q2 2022 Aug 11, 2022	BUY	$7.31 - $12.84 $33,830 - $59,423	4,628 Added 8.63%	58,281 $583,000
Q1 2022 May 12, 2022	BUY	$9.74 - $17.69 $212,185 - $385,376	21,785 Added 68.36%	53,653 $660,000
Q4 2021 Feb 14, 2022	BUY	$16.88 - $23.31 $13,402 - $18,508	794 Added 2.56%	31,868 $553,000
Q3 2021 Nov 16, 2021	BUY	$16.82 - $25.75 $522,664 - $800,155	31,074 New	31,074 $558,000

154

27.3M

515K

838K

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $581M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

Get notified when there are updates to the investment portfolio of Cetera Advisor Networks LLC, based on Form 13F filings with the SEC.

Stay updated on Cetera Advisor Networks LLC with notifications on news.